Abstract:Objective: To review recent research advances on tau, a major player in Alzheimer's disease (AD) pathogenesis, a biomarker for AD onset, and potential target for AD therapy. Data sources: This review was based on a comprehensive search using online literature databases, including PubMed, Web of Science, and Google Scholar. Study selection: Literature search was based on the following keywords: Alzheimer's disease, tau protein, biomarker, cerebrospinal fluid (CSF), therapeutics, plasma, imaging, propagation, spreading, seeding, prion, conformational templating, and posttranslational modification. Relevant articles were carefully reviewed, with no exclusions applied to study design and publication type. Results: Amyloid plaques enriched with extracellular amyloid beta (Aβ) and intracellular neurofibrillary tangles comprised of hyperphosphorylated tau proteins are the two main pathological hallmarks of AD. Although the Aβ hypothesis has dominated AD research for many years, clinical Aβ-targeting strategies have consistently failed to effectively treat AD or prevent AD onset. The research focus in AD has recently shifted to the role of tau in AD. In addition to phosphorylation, tau is acetylated and proteolytically cleaved, which also contribute to its physiological and pathological functions. Emerging evidence characterizing pathological tau propagation and spreading provides new avenues for research into the molecular and cellular mechanisms underlying AD pathogenesis. Techniques to detect tau at minute levels in CSF and blood have been developed, and improved tracers have facilitated tau imaging in the brain. These advances have potential to accurately determine tau levels at early diagnostic stages in AD. Given that tau is a potential therapeutic target, anti-tau immunotherapy may potentially be a viable treatment strategy in AD intervention. Conclusion: Detecting changes in tau and targeting tau pathology represent a promising lead in the diagnosis and treatment of AD.

Advances in Tau-mediated neurodegeneration and Tau-focused drug for Alzhehimer's disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Recent developments with tau-based drug discovery

Self-assembly Hollow Manganese Prussian White Nanocapsules Attenuate Tau-related Neuropathology and Cognitive Decline.

Advances in the Pathogenesis of Alzheimer’s Disease: Focusing on Tau-Mediated Neurodegeneration

Progress of tau-targeted therapy in Alzheimer's disease

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies.

Development of multiple-target anti-Alzheimer′s agents

Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy

Current Advances in the Treatment of Alzheimer's Disease: Focused on Considerations Targeting Aβ and Tau

New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease

Advances In Recent Patent And Clinical Trial Drug Development For Alzheimer'S Disease

Progress in pathogenesis and treatment of Alzheimer's disease

Advances in the Research on Targets for Drug Discovery for Alzheimers Disease Supported by NSFC

Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance

Advances in targets of pharmacotherapy and discovery of new drugs for Alzheimer disease:do we have any novel strategies?

Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer's Diseases

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development